Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.1952W HIGH $9.71
Volume
11.05 K
Value Traded
2.30 M
Short % Float
3.52%
-0.7%Week
+5.22%1 Month
+59.21%3 Month
+145.51%6 Month
-83.23%5 Year
-83.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
464.67 M
EPS (TTM)
-0.54
P/E Ratio
-
Ent. Value
427.62 M
Total Shares
55.09 M
Float Shares
35.57 M
Insiders
35.44%
Institutions
40.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SGHT Catalyst Timeline
Dated clinical, regulatory and corporate events for Sight Sciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sight Sciences, Inc.
238Total events
1Upcoming
44Tier-1 (high impact)
2021 to 2026Coverage
Event history 50
▲Label ExpansionTearCareFDA Decision
FDA updates TearCare Indications for Use to include improvement of meibomian gland function
evaporative dry eye disease due to meibomian gland dysfunctionsource ↗
▲FDA ApprovalFDA Decision
FDA 510(k) clearance of OMNI Ultra Surgical System
primary open-angle glaucomasource ↗
▲Other Regulator MilestoneOMNIEx-US Regulatory
Aetna coverage policy recognizes OMNI as medically necessary
mild-to-moderate open-angle glaucomasource ↗
▲Other Regulator MilestoneSIONEx-US Regulatory
Aetna coverage policy recognizes SION as medically necessary
mild-to-moderate open-angle glaucomasource ↗
▲Quarterly UpdateTearCareCorporate
Added 4.1 million patient lives for TearCare reimbursement
dry eye diseasesource ↗
▲Other Regulator MilestoneTearCareEx-US Regulatory
Expanded patient lives with access to TearCare reimbursement
dry eye diseasesource ↗
▲IP Litigation RulingIP / Competition
Final judgment in patent infringement case against Alcon, awarding $55.4M damages and 10% ongoing royalty
glaucomasource ↗
◆Oral PresentationPresentation
Sight Sciences to present at 25th Annual Needham Healthcare Conference
◆Oral PresentationPresentation
Outcomes for Localized Heat Therapy (LHT) or Cyclosporine in Dry Eye Disease (DED) Signs and Symptoms by Baseline Severity
dry eye diseasesource ↗
◆Poster PresentationPresentation
Clinically Relevant Change in Tear Break-up Time (TBUT) with Localized Heat Therapy or Cyclosporine in Dry Eye Disease (DED)
dry eye diseasesource ↗
◆Poster PresentationPresentation
Longer-term Diurnal IOP (DIOP) Fluctuations Following Canaloplasty and Trabeculotomy (CT) with and without cataract surgery
primary open-angle glaucomasource ↗
▲IP Litigation RulingIP / Competition
Court issued order preserving jury verdict of willful infringement and awarding $34M damages plus ongoing royalty
▼Quarterly UpdateCorporate
Sight Sciences reported Q4 and full year 2025 financial results and initiated FY2026 guidance
◆Oral PresentationPresentation
Sight Sciences management to present at Piper Sandler 37th Annual Healthcare Conference
◆Long Term DataTearCareClinical Data
SAHARA RCT 24-month results expected 2H 2025
dry eye diseasesource ↗
▲PublicationPresentation
Publication of three manuscripts on OMNI Surgical System with TruSync Technology
glaucomasource ↗
◆Oral PresentationPresentation
Sight Sciences management to present at Stifel 2025 Healthcare Conference
▲Other Regulator MilestoneEx-US Regulatory
UnitedHealthcare expanded coverage policy for OMNI procedures effective October 1, 2025
open-angle glaucomasource ↗
◆Quarterly UpdateCorporate
Q3 2025 earnings call with updated revenue and adjusted operating expenses guidance
▲REMS ModifiedTearCarePost-Market
New carrier-priced fee schedules established for TearCare
evaporative dry eye disease due to meibomian gland diseasesource ↗
▲PublicationPresentation
Publication of systematic review and meta-analysis of OMNI in European Journal of Ophthalmology
open-angle glaucomasource ↗
▲Oral PresentationPresentation
Presentation of meta-analysis findings at ESCRS meeting in Copenhagen
open-angle glaucomasource ↗
◆Oral PresentationPresentation
Sight Sciences to present at Morgan Stanley Global Healthcare Conference
▲Full ResultsClinical Data
Cost-utility analysis comparing TearCare to cyclosporine 0.05% published
meibomian gland disease associated dry eye diseasesource ↗
▲PublicationTearCarePresentation
Cost-utility analysis of TearCare vs cyclosporine 0.05% published in Expert Review of Pharmacoeconomics & Outcomes Research
moderate to severe meibomian gland disease associated dry eye diseasesource ↗
▲Full ResultsTearCareClinical Data
24-month results of SAHARA RCT published in Optometry and Vision Science
dry eye diseasesource ↗
▲PublicationPresentation
TearCare System included in TFOS DEWS III report published in American Journal of Ophthalmology
dry eye diseasesource ↗
◆Oral PresentationPresentation
Sight Sciences to present at Stifel 2025 Virtual Ophthalmology Forum
▲Product LaunchPost-Market
Launch of OMNI Edge Surgical System at ASCRS 2025
primary open-angle glaucomasource ↗
●Oral PresentationPresentation
Debut of OMNI Edge at ASCRS Annual Meeting
primary open-angle glaucomasource ↗
◆Oral PresentationPresentation
Sight Sciences to present at 24th Annual Needham Healthcare Conference
▲Product LaunchPost-Market
Launched OMNI Edge at ASCRS Annual Meeting
primary open-angle glaucomasource ↗
▲Full ResultsClinical Data
Publication of 36-month analysis of OMNI Surgical System
primary open-angle glaucomasource ↗
▲Full ResultsClinical Data
Publication of Budget Impact Analysis of TearCare System
meibomian gland disease associated dry eye diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How SGHT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Sight Sciences, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SGHT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OMNI Surgical System | primary open-angle glaucoma | 2025-02-24 | clinically and statistically significant reductions in IOP through 24 months; statistically significant reductions in medication through 36 monthsRead More | Sight Sciences to Present Comprehensive Clinical Data on the OMNI Surgical System at the 2025 American Glaucoma Society Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rodberg JamesOfficer (Chief Financial Officer) | Sell | -7,208 216,829 held | $8.85 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SGHT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.2 % | 3.37 M | 425.00 K |
SGHT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SGHT ranks across every disease it competes in
Competitive Position is a premium feature
See how SGHT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSGHT News
SGHTSight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
Sight Sciences has announced the launch of the OMNI Ultra Surgical System, an advanced technology for glaucoma treatment, set to debut at the 2026 AAO Annual Meeting. This system enhances procedural flexibility and addresses multiple areas of resistance in the eye's outflow pathway. The company aims to improve patient outcomes through innovative, implant-free interventions.
Read more →SGHTSight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
Sight Sciences, Inc. will present at the Morgan Stanley Global Healthcare Conference on September 15, 2026. The company specializes in developing innovative eyecare technologies aimed at transforming patient care. Their products, including the OMNI and TearCare systems, focus on treating common eye diseases with minimally invasive techniques. The presentation will be accessible via a live webcast.
Read more →SGHTTearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
Sight Sciences, Inc. announced that the FDA has updated the indications for the TearCare System, making it the first treatment specifically indicated to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction. This update emphasizes the importance of addressing the underlying causes of dry eye disease and enhances the treatment landscape for affected patients.
Read more →SGHT▲ +27.7%on this news· ran to +40% by day 3
Sight Sciences Reports Second Quarter 2026 Financial Results
Sight Sciences reported strong financial results for Q2 2026, with revenue reaching $23.4 million, a 20% increase from the previous year. The Interventional Dry Eye segment saw a remarkable 704% growth, contributing to overall revenue growth. The company also improved its cash usage and received FDA clearance for a new surgical system, while raising its revenue guidance for the year.
Read more →SGHT▲ +27.7%on this news· ran to +40% by day 3shared move
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems
Sight Sciences announced that Aetna has updated its Glaucoma Surgery Policy to include coverage for the OMNI and SION surgical systems as medically necessary for treating mild-to-moderate open-angle glaucoma. This change, effective retroactively from July 14, 2026, establishes broader access to these innovative technologies, reinforcing their role in glaucoma treatment. The company emphasizes the importance of this milestone for improving patient care.
Read more →SGHTSight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
Sight Sciences, Inc. has received FDA 510(k) clearance for its OMNI Ultra Surgical System, designed for canaloplasty and trabeculotomy to reduce intraocular pressure in patients with primary open-angle glaucoma. This innovative device offers a comprehensive, implant-free solution and enhances surgical precision. The company plans to launch the system commercially in the fourth quarter of 2026.
Read more →SGHT▼ -6.6%on this news
Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Sight Sciences, Inc. will report its financial results for Q2 2026 on August 5, 2026. The announcement includes a conference call for management to discuss the results. The company specializes in innovative eyecare technologies aimed at transforming patient care. Their products include minimally invasive solutions for glaucoma and dry eye disease.
Read more →SGHTSight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
Sight Sciences reported a strong start to 2026, with a 13% increase in revenue to $19.7 million in Q1. The company also raised its full-year revenue guidance, driven by significant growth in Interventional Dry Eye products. Despite a net loss of $13.0 million, the company demonstrated improved cash management and operational efficiency.
Read more →SGHT▼ -8.9%on this news
Sight Sciences to Present at Two Upcoming Investor Conferences
Sight Sciences, an eyecare technology company, announced its participation in two upcoming investor conferences: the BofA Securities 2026 Health Care Conference on May 13, 2026, and the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026. The company focuses on developing innovative technologies aimed at transforming eye care, particularly addressing prevalent eye diseases. Interested parties can access webcasts of the presentations on their investors' page.
Read more →SGHTSight Sciences Announces the Release of its Sustainability Report
Sight Sciences, an eyecare technology firm, has released its third annual Sustainability Report, which outlines its environmental and social initiatives over the past three years. The report highlights significant progress in transparency, operational discipline, and a more than 20% reduction in emissions in 2025. Additionally, the company has supported various community engagement programs, donating to initiatives that aid indigent care in 24 different countries. With a workforce where 56% are women, Sight Sciences emphasizes its commitment to diversity and effective governance practices.
Read more →SGHTSight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
Sight Sciences, Inc. announced it will report its first quarter financial results for 2026 on May 6, 2026, after market close. The management will host a conference call to discuss the results at 1:30 p.m. PT. The company specializes in innovative eyecare technologies aimed at improving patient care.
Read more →SGHTSight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Sight Sciences, Inc. will present data on its glaucoma and dry eye technologies at the 2026 ASCRS Annual Meeting. The OMNI Surgical System and TearCare System will be highlighted, showcasing their effectiveness in reducing intraocular pressure and improving tear film stability. The presentations aim to support broader adoption of these technologies among eyecare providers.
Read more →SGHT▼ -5.2%on this newsshared move
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
Sight Sciences has secured a favorable ruling from the U.S. District Court, which upheld the jury's verdict of willful patent infringement by Alcon regarding its Hydrus Microstent. The court awarded Sight Sciences $34 million in damages and established ongoing royalties of 10% on Hydrus sales until the expiration of its last asserted patent in 2028. However, the final judgment is subject to appeal and may be influenced by ongoing reexamination proceedings initiated by Alcon.
Read more →SGHT▼ -5.2%on this newsshared move
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
Sight Sciences, Inc. announced its participation in the 25th Annual Needham Healthcare Conference, scheduled for April 13, 2026. The presentation will be accessible via a live and archived webcast. The company specializes in developing innovative eyecare technologies aimed at improving patient outcomes, particularly in glaucoma and dry eye disease treatments.
Read more →SGHT▼ -26.8%on this newsshared move
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance
Sight Sciences reported its financial results for Q4 and full year 2025, highlighting a 7% revenue increase in Q4. The company also initiated guidance for 2026, projecting revenue growth of 6% to 14%. Despite a net loss of $38.4 million for 2025, management remains optimistic about achieving cash flow breakeven in the coming year.
Read more →SGHTSight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Sight Sciences, Inc. has announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on March 4, 2026. The report will follow a conference call scheduled for 1:30 p.m. PT, where management will discuss the results. The company's focus on innovative, minimally invasive eyecare technologies aims to improve patient care and align with advancements in treatment modalities for prevalent eye diseases.
Read more →SGHT▼ -7.8%on this news
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2025, indicating a 7% revenue growth in Q4 but a 3% decrease for the full year. The company maintains a strong cash position of approximately $92 million and has made significant progress in Dry Eye reimbursement. Full financial results are expected in March 2026.
Read more →SGHT▲ +8%on this news· ran to +18% by day 1
New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans
Sight Sciences, Inc. has announced positive results from three peer-reviewed studies on its OMNI Surgical System with TruSync Technology. The studies highlight the system's effectiveness in reducing intraocular pressure and medication reliance in glaucoma patients, particularly among African Americans. The findings support the use of interventional treatments in managing glaucoma.
Read more →SGHT▲ +16.4%on this news· ran to +54% by day 3shared move
Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
Sight Sciences, Inc. reported its third-quarter financial results for 2025, revealing a slight revenue decline but an increase in Surgical Glaucoma revenue. The company raised its full-year revenue guidance and reduced its operating expenses, reflecting operational efficiencies. However, the Dry Eye segment faced significant revenue challenges, impacting overall financial performance.
Read more →SGHT▲ +16.4%on this news· ran to +54% by day 3shared move
Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer
Sight Sciences has appointed Alison Bauerlein as Chief Operating Officer and James Rodberg as Chief Financial Officer, effective November 5, 2025. Both leaders bring extensive experience in medtech and finance, which aligns with the company's goals to enhance its market position and improve patient care. The appointments are seen as crucial for scaling operations and driving growth in the interventional dry eye category.
Read more →About Sight Sciences, Inc.
Headquarters4040 CAMPBELL AVE,, MENLO PARK, CA, 94025
BIOPHARMAWATCH ELITE PLUS
Trade the next SGHT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime